Search PubMed⌕ Search

Biomedical subjects

T Kotake

Publications and source records attributed to T Kotake.

At least 253 records · Page 14Linked to original sources
PubMed1983

Circulating cytotoxic anti-RCC antibody responses in renal cell carcinoma patients.

The circulating anti-RCC cytotoxic antibodies of eighteen RCC patients, preoperatively, and one inoperable case were studied by 51Cr release CDC and ADCC assays, using the cultured human RCC cell line, OUR-10. Circulating cytotoxic anti-RCC antibodies were detected in eight patients as CDC antibodies. The patients with a low pathological grade had a significantly higher percentage (P less than 0.05) of positive antibody responses.

Adenocarcinoma↗
PubMed1983

[Experience with transabdominal and scrotal ultrasonographic examination in urology].

To evaluate its diagnostic availability in urology, transabdominal and scrotal ultrasonographic examination was made on 87 patients who had been admitted to our hospital for space occupying lesions. In retroperitoneal lesions, adrenal tumors and renal tumors greater than 2.5 cm could be detected by this examination. In pelvic lesions, bladder tumors greater than 0.5 cm were demonstrated and prostatic carcinoma with heterogeneous echotexture and irregular margin was discriminated from BPH. Not only could fluid-filled scrotal lesions larger than 1.0 cm be distinguished from solid mass lesions, but the intrascrotal anatomy could also be demonstrated in detail. Because of its safety, flexibility, and accuracy in detecting space occupying lesions, this examination could be a useful screening test in urology. Representative cases we experienced are presented.

Abdomen↗
PubMed1982

[Chemotherapy of hormone-unresponsive prostatic cancer and its metastatic foci].

This article is a review of the results of chemotherapy for advanced hormonally-unresponsive prostatic carcinoma. Although the only hope for treatment of these patients is chemotherapy, until recently relatively little emphasis has been placed on chemotherapy of prostatic cancer. Since results of the randomized trial of the National Prostatic Cancer Project in the United States revealed a demonstrable advantage of advanced hormonally-refractory disease, a number of studies has been done and reported. As single chemotherapeutic agent, cyclophosphamide (CPM), 5-fluorouracil (5-FU), Adriamycin (ADM), and Cisplatinum (CDDP) have activity in these patients. Estracyt has been reported very effective, but has been somewhat disappointing in American trials. Several combination chemotherapies have been reported effective, such as CPM + ADM, CPM + ADM + Methotrexate (MTX), and CPM + MTX + 5-FU + Vincristine, Prednisone. Presently, however, there is no evidence that combination chemotherapy in prostatic cancer is better than single-agent chemotherapy. The need for continued effort to search powerful new agent, and to establish more effective combination chemotherapy for prostatic cancer should be emphasized. Furthermore, the importance of randomized and stratified clinical trials, early and late in the course of the disease, is stressed.

Androgen Antagonists↗
PubMed1981

Total retropubic prostatectomy for carcinoma of the prostate.

Total prostatectomy is an effective mode of therapy for early carcinoma of the prostate. This report deals with 74 patients who underwent total retropubic prostatectomy at our hospitals during a 23-year period. The 5-year survival rates of patients with stages A and B, C, and D carcinomas were 84.1, 40.1, and 12.7% respectively. The total 5-year survival rate was 56.1%. The 10-year survival rates compare favorably with those of any other mode of therapy. The histological grade was highly significant with respect to prognosis. Combined orchiectomy with total prostatectomy was effective. Operative mortality was 4.05% (3 patients), and the main complication was incontinence. We strongly believe that total prostatectomy is the only curative treatment for early carcinoma of the prostate. This procedure should be utilized more frequently.

Aged↗
PubMed1981

Gamma-glutamyl transpeptidase in a newly established cell line from human renal carcinoma, OUR-10.

A newly established cell line, OUR-10, from human renal carcinoma seems to have the same gamma-glutamyl transpeptidase as the novel one which was found recently in renal carcinoma tissue; the enzymic properties such as electrophoretic mobility, Km value, molecular weight, thermostability, the effects of urea, sodium dodecyl sulfate and sulfhydryl reagents, the effects of amino acids, cations and EDTA, and the binding behavior to a concanavalin A-Sepharose column were the same as those of the novel gamma-glutamyl transpeptidase found in renal carcinoma tissue. The immunological properties of the gamma-glutamyl transpeptidase (GGTP) of OUR-10 examined by inhibition tests and tests of cross-reactivity with anti-normal kidney GGTP antibody were also the same as those of the novel gamma-glutamyl transpeptidase. These results may mean that the novel gamma-glutamyl transpeptidase originates from the cancer cells, and can be used as a marker for identification of this cell line, OUR-10.

Adult↗
PubMed1980

Lactate dehydrogenase in human renal carcinoma tissues.

Lactate dehydrogenase (LDH) activity and isoenzyme were determined in 27 human renal carcinoma (RC) tissues. Although LDH-1 and LDH-2 were predominant in the normal kidney, a completely inverted isoenzyme pattern was observed in 16 carcinomas. The others, however, showed either a normal or an incompletely inverted pattern. The LDH activity in the tumours with a completely inverted pattern was significantly higher than the activity of incompletely inverted or normal kidney pattern. It was also found that the isoenzyme pattern was more closely correlated with cell type than the grade of malignancy of the tumour, 14 out of the 16 cases of the completely inverted pattern being of the clear cell type, and 9 out of the 11 cases of incompletely inverted or normal kidney pattern being of either granular cell or mixed cell type. These results seemed to well substantiate an opinion that in clear cells anaerobic glycolysis provides a major energy source, whereas granular cells seek energy source primarily in TCA cycle and subsequent oxidative phosphorylation.

Adenocarcinoma↗
PubMed1979

A new screening method for cystinuria. A simple and safe screening kit.

The new kit (Urocystin) presented here utilizes the dark brown coloration which a neutral aqueous solution of cystine develops rapidly upon addition of nickel ion and sodium hydrosulfite (Na2S2O4). What is needed is pouring 4 ml of the urine sample into the kit, and the kit is able to judge without fail any urine sample with a cystine concentration of 50 microgram/ml or more as positive. No pretreatment of the sample is necessary. The kit contains no hazardous reagents at all. The kit has thus turned screening of cystinuria into an extremely simple affair.

Cystinuria↗
PubMed1979

Another Kasahara-variant alkaline phosphatase in renal cell carcinomas.

Another Kasahara-variant alkaline phosphatase isoenzyme was found in 2 out of 25 human renal cell carcinoma tissues. This enzyme electrophoresed in a single diffuse band which is cathodal to but continuous with the liver alkaline phosphatase. After neuraminidase treatment, this enzyme electrophoresed in the same position as that of neuraminidase-treated Kasahara isoenzyme. The enzymic properties of another neuraminidase-treated Kasahara-variant enzyme such as inhibitions by L-phenylalanine, L-homoarginine, L-tryptophan, and L-leucine, effects of inorganic phosphate, urea, and sodium dodecyl sulfate, heat stability, and the reactivity with concanavalin-A are consistent with those of Kasahara isoenzyme. On Ouchterlony's double diffusion, the precipitin lines of Kasahara and the new variant enzyme produced by antibody to Kasahara isoenzyme fused completely. These facts may indicate the occurrence of another Kasahara-variant isoenzyme.

Adenocarcinoma↗
PubMed1979

Characterization of an established cell line from human renal carcinoma.

A cell line, designated as OUR-10, has been established from a renal carcinoma in a Japanese woman. This cell line forms monolayers of polygonal epithelial cells with scattered round or dendritic cells and exhibits multilayering. With electron microscopy, differentiated surface structures that resemble the microvilli characteristic of renal carcinomas can be seen even at the 60th transfer. The cells have a hypodiploid karyotype with modal numbers of 39 and 40. No marker chromosomes were seen, but definite nonrandom loss of three chromosomes in Group D and one in Group E were recognized. The doubling time was estimated as approximately 32 hr in exponentially growing cultures, and the cells formed colonies in soft agar with an average efficiency of 25%. Heterotransplantation into the cheek pouch of immunosuppressed hamsters produced tumors that were histologically similar to the original cancerous tissue. The electrophoretic mobility of gamma-glutamyl transpeptidase extracted from the cells coincided with that of a novel isozyme found in human renal carcinoma tissue, and the genetic phenotype of the glucose-6-phosphate dehydrogenase was proved to be the B phenotype. The antigenic structure of HLA was determined as HLA-A2, 11; B5, 40, which was the same as that of peripheral blood lymphocytes of the woman with renal carcinoma.

Adenocarcinoma↗